Healthcare / BiotechnologyLSE
$0.18
-0.01 (-7.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.7M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-44.4%
↓Gross Margin
100.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3260.7%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $49775.0 · net income $-1.9M · FCF $-1.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $49775.00 | $49775.00 | $9600.00 | — | — |
| Net Income | $-1.9M | $-1.9M | $-2.0M | $-2.4M | $-1.5M |
| EBITDA | $-1.9M | $-1.9M | $-2.0M | $-2.4M | $-1.4M |
| EPS | — | — | -0.02 | -0.03 | -0.02 |
| Gross Margin | 100.0% | 100.0% | 85.0% | — | — |
| Operating Margin | -4302.7% | -4302.7% | -23943.1% | — | — |
| Net Margin | -3848.7% | -3848.7% | -21226.1% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 9.66 | 9.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.6M | $-1.6M | $-2.1M | $-1.7M | $-1.3M |
| Returns | |||||
| ROE | -44.4% | -44.4% | -63.3% | -58.4% | -42.2% |
| Valuation | |||||
| P/B | 15.61 | 15.61 | 190.92 | 243.31 | 532.79 |
| Growth & Yield | |||||
| Revenue Growth | 418.5% | 418.5% | — | — | — |
| EPS Growth | — | — | 34.3% | -30.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-62.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → n/d
Residual
-62.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.